Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

6.81
+0.05000.74%
Post-market: 6.810.00000.00%16:10 EDT
Volume:488.53K
Turnover:3.31M
Market Cap:146.36M
PE:-4.25
High:6.89
Open:6.80
Low:6.61
Close:6.76
52wk High:11.00
52wk Low:3.71
Shares:21.49M
Float Shares:13.01M
Volume Ratio:1.48
T/O Rate:3.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6020
EPS(LYR):-5.6466
ROE:-102.29%
ROA:-44.23%
PB:3.90
PE(LYR):-1.21

Loading ...

Positioning Oxylanthanum Carbonate for Category-Defining Growth via TDAPA Advantage, Regulatory Clarity, and Robust Shareholder Returns

TIPRANKS
·
Mar 18

Unicycive Therapeutics Publishes Corporate Presentation on Kidney Disease Pipeline and OLC Hyperphosphatemia Program

Reuters
·
Mar 06

Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY)

TIPRANKS
·
Mar 02

Unicycive Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Feb 20

Unicycive Therapeutics initiated with a Buy at WestPark Capital

TIPRANKS
·
Feb 19

Unicycive Therapeutics Faces Shareholder Lawsuit Over Alleged False Statements

Reuters
·
Feb 17

Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and Launch Plans for OLC

Reuters
·
Feb 07

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit

GlobeNewswire
·
Feb 04

Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments

Reuters
·
Jan 31

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jan 30

De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC

TIPRANKS
·
Jan 30

BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin

Reuters
·
Jan 29

Unicycive Therapeutics Inc - FDA Assigns Pdufa Target Date of June 29, 2026

THOMSON REUTERS
·
Jan 29

Update - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (Olc) New Drug Application (Nda) Resubmission

THOMSON REUTERS
·
Jan 29

BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug

Reuters
·
Jan 29

Unicycive Therapeutics Inc - Pdufa Target Action Date Set for June 27, 2026

THOMSON REUTERS
·
Jan 29

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission

GlobeNewswire
·
Jan 29

Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation

Reuters
·
Jan 08

Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA

Reuters
·
Dec 29, 2025

Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act

THOMSON REUTERS
·
Dec 29, 2025